Thanks for the news Cronkite. About as on top of it as Obama hearing about the latest scandal in the mainstream media.
Actually we have:
Jul 7, 2014 5,372,100
Jul 3, 2014 3,273,700
Jul 2, 2014 6,487,100
Jul 1, 2014 3,525,500
Jun 30, 2014 8,561,200
Jun 27, 2014 7,660,200
Jun 26, 2014 3,661,800
Jun 25, 2014 5,217,900
Jun 24, 2014 3,975,200
Jun 23, 2014 3,346,900
And with a PET scan costs $3500 a pop vs a blood test like Lympro that GC has said it will be 25% of that cost
Gauge motivations by timing of posting versus price. Just saying.
I am not a scientist, but if I interpret the definition of longitudinal study correctly, Poster 3 is just an updated observational report on how accurate the original data from 2008 was. In other words, they ran some tests in 2008, made a diagnosis and have now come back to see how they did using that original testing method. In the intervening time frame there have been advances in the testing procedures which have increased accuracy and that is what Poster 1 was indicating and what the Bridging Data will hopefully show between the original work and Lympro 1 and Lympro 2 under the Amarantus custodianship correct?
The fool who posts or the fool who responds to the fool? Put them on ignore. Soon they will go away because no one will engage in their attempts at being self important. They migrate here because they have worn out their welcome in other spots. Let that occur again and the board will be better once again.
Of course pumping is being done here. It is plain to see. I just hate the high and mighty who think they have a monopoly on the truth and will set us poor suckers straight. They usually have the greatest agenda of all. We all know that riskreturn, pais, and several others ball wash AMBS on a constant basis and probably do play the swings, contrary to their protests that they don't. I have healthy skepticism as most investors should, but it is quite clear about this particular poster what their angle is.
Another douche who shows up throwing around a pile of #$%$ and hoping it sticks to the walls. Amazing how this poster comes out of the shadows now and claims he doesn't care about AMBS, just wants to shed the light of truth on the seedy underbelly of the paid promotion. Right. Everyone has an agenda. His is clear. Put the idiot on ignore and do your own due diligence.
$40. No wait, $0.40. Your question is too unfocused. Realistically short term being the end of the year, probably in the $0.25 - $0.30 range ifffff revenue guidance per Gerald is announced on the Q2 conference call and the market likes it. Ifffff the Lympro data is as good as it is sounding for specificity and sensitivity. Iffff the CLIA package is submitted and accepted. Iffff there is a partner announcement and a reasonable agreement is made in terms of upfront and royalty payments on Lympro.......do you get the point???
Interesting points in the article in the Financial Times. Specifically that 400 plus people with Alzheimers were included in the research. Interesting. I only though Alzheimers could be definitively diagnosed from autopsy. So that is a great trick they are pulling using a differential observed behavior method to declare that someone has Alzheimers to try and test for Alzheimers. Brilliant.